ORKA Oruka Therapeutics, Inc.

USD 10.15 +0.59 ( +6.17%)
Icon

Oruka Therapeutics, Inc. (ORKA) Financial Statements

COMMON STOCK | Others | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 10.15

+0.59 (+6.17%)

USD 0.89B

0.21M

USD 40.60(+300.00%)

USD 15.00 (+47.78%)

Icon

ORKA

Oruka Therapeutics, Inc. (USD)
COMMON STOCK | NSD
USD 10.15
+0.59 ( +6.17%)

Oruka Therapeutics, Inc. (ORKA) Annual Income Statement (USD)

ORKA Quarterly Financials (USD)

Frequently Asked Questions About Oruka Therapeutics, Inc. (ORKA) Stock

Oruka Therapeutics, Inc.'s (ORKA) last reported annual revenue was N/A.

Oruka Therapeutics, Inc.'s (ORKA) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A

Oruka Therapeutics, Inc.'s(ORKA) is not profitable as of its last reported annual financials.

The net profit margin for Oruka Therapeutics, Inc.'s(ORKA) from its laster reported year is N/A

The return on equity (ROE) for Oruka Therapeutics, Inc.'s(ORKA) from its last reported annual financials is : 0.00%

The return on assets (ROA) for Oruka Therapeutics, Inc.'s(ORKA) from its last reported annual financials is : 0.00%

The return on invested capital (ROIC) for Oruka Therapeutics, Inc.'s(ORKA) from its last reported annual financials is : 0.00%

The Debt to Equity ratio for Oruka Therapeutics, Inc.'s(ORKA) from its last reported annual financials is : 0.00%

The dividend yield for Oruka Therapeutics, Inc.'s(ORKA) from its laster reported year is 77.77%

Oruka Therapeutics, Inc.'s(ORKA) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...